Sílvia Casacuberta-Serra

Sílvia Casacuberta-Serra

Auto-generated profile, based on publicly available information

Sílvia Casacuberta-Serra

Peptomyc S.L.

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MBMarie-Eve Beaulieu
Marie-Eve Beaulieu
TJToni Jauset
Toni Jauset
DMDaniel Massó-Vallés
Daniel Massó-Vallés
SMSandra Martínez-Martín
Sandra Martínez-Martín
PRPeter Rahl
Peter Rahl
LSLaura Soucek
Laura Soucek
We demonstrate the pharmacologic potential of the purified cell-penetrating Omomyc mini-protein to directly inhibit MYC function in vitro and in vivo.

21 August 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
SCSílvia Casacuberta-Serra
Sílvia Casacuberta-Serra
ILIñigo González Larreategui
Iñigo González Larreategui
DCDaniel Capitán-Leo
Daniel Capitán-Leo
LSLaura Soucek
Laura Soucek
RAS and MYC rank amongst the most commonly altered oncogenes in cancer, with RAS being the most frequently mutated and MYC the most amplified. The cooperative interplay between RAS and MYC constitutes a complex and multifaceted phenomenon, profoundly influencing tumor development. Together and individually, these two oncogenes regulate most, if not all, hallmarks of cancer, including cell death escape, replicative immortality, tumor-associated angiogenesis, cell invasion and metastasis, metabolic adaptation, and immune evasion. Due to their frequent alteration and role in tumorigenesis, MYC and RAS emerge as highly appealing targets in cancer therapy. However, due to their complex nature, both oncogenes have been long considered “undruggable” and, until recently, no drugs directly targeting them had reached the clinic. This review aims to shed light on their complex partnership, with special attention to their active collaboration in fostering an immunosuppressive milieu and driving immunotherapeutic resistance in cancer. Within this review, we also present an update on the different inhibitors targeting RAS and MYC currently undergoing clinical trials, along with their clinical outcomes and the different combination strategies being explored to overcome drug resistance. This recent clinical development suggests a paradigm shift in the long-standing belief of RAS and MYC “undruggability”, hinting at a new era in their therapeutic targeting.

2 March 2021 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
MZMariano F Zacarías-Fluck
Mariano F Zacarías-Fluck
TJToni Jauset
Toni Jauset
SMSandra Martínez-Martín
Sandra Martínez-Martín
JKJastrinjan Kaur
Jastrinjan Kaur
SCSílvia Casacuberta-Serra
Sílvia Casacuberta-Serra
LSLaura Soucek
Laura Soucek
The huge cadre of genes regulated by Myc has obstructed the identification of critical effectors that are essential for Myc-driven tumorigenesis. Here, we describe how only the lack of the receptor Fzd9, previously identified as a Myc transcriptional target, impairs sustained tumor expansion and β-cell dedifferentiation in a mouse model of Myc-driven insulinoma, allows pancreatic islets to maintain their physiological structure and affects Myc-related global gene expression. Importantly, Wnt signaling inhibition in Fzd9-competent mice largely recapitulates the suppression of proliferation caused by Fzd9 deficiency upon Myc activation. Together, our results indicate that the Wnt signaling receptor Fzd9 is essential for Myc-induced tumorigenesis in pancreatic islets.

23 January 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ÍGÍñigo González-Larreategui
Íñigo González-Larreategui
MMManrique Valdés-Bango Martín
Manrique Valdés-Bango Martín
SCSílvia Casacuberta-Serra
Sílvia Casacuberta-Serra
LSLaura Soucek
Laura Soucek
Immunotherapies have transformed cancer treatment by harnessing the immune system to recognize and eliminate malignant cells, offering durable clinical benefit across diverse tumor types. Despite successes with immune checkpoint inhibitors (ICIs) and other strategies like cytokines, oncolytic viruses, cancer vaccines, bispecific antibodies, and adoptive cell therapies, substantial fractions of patients still fail to respond or develop resistance. The oncogene MYC, deregulated in ~70% of human cancers, has emerged as a central driver of immune evasion and a key contributor to immunotherapy failure. MYC regulates broad transcriptional networks controlling proliferation, metabolism, angiogenesis, and cell survival, while also orchestrating profound remodeling of the tumor microenvironment (TME). Mechanistically, oncogenic MYC suppresses antigen processing and presentation, attenuates interferon signaling, and upregulates immune checkpoints such as PD-L1 and CD47. Concurrently, MYC stimulates secretion of immunosuppressive cytokines and chemokines that recruit regulatory T cells, myeloid-derived suppressor cells, and M2 macrophages, while driving metabolic reprogramming that fosters nutrient competition, hypoxia, and acidosis, impairing effector T- and NK-cell function. Through these pathways, MYC promotes primary, adaptive, and acquired resistance to immunotherapy. Targeting MYC, directly or indirectly, holds promise to restore immune surveillance and potentiate immunotherapeutic efficacy. This review highlights MYC as a master regulator of tumor–immune interactions and underscores the therapeutic potential of MYC inhibition to overcome resistance and expand the clinical impact of cancer immunotherapy.


4 April 2023
Verified
Other
Open access
DMDaniel Massó-Vallés
Daniel Massó-Vallés
MBMarie-Eve Beaulieu
Marie-Eve Beaulieu
TJToni Jauset
Toni Jauset
FGFabio Giuntini
Fabio Giuntini
MZMariano F. Zacarías-Fluck
Mariano F. Zacarías-Fluck
LSLaura Soucek
Laura Soucek